Tristel PLC
22 July 2026
Tristel plc
("Tristel" or the "Company")
Positive Trading Update
Results in line with market expectations
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces a trading update for the year ended 30 June 2026 ("FY 2026"). The Company confirms another year of significant growth with results expected to be in line with market expectations1 and the Company's own performance targets.
FY 2026 Financial Highlights
· Revenues up 10% to £51.1m (FY 2025: £46.5m)
· Adjusted EBITDA margin remains comfortably above the 25% target
· 14% growth in adjusted profit before tax2 which is expected to be no less than £11.5m, marginally above market expectations (FY 2025: £10.1m)
· Tristel continues to be debt free and cash generative which supports continued growth in overseas territories
· Cash balances on 30 June 2026 were £16.0m (30 June 2025: £12.8m)
1 Management understands consensus forecasts for FY 2026 to be revenues of £51.1m and adjusted PBT of £11.4m
2 Adjusted for share-based payments, exceptional items and Research and Development tax credit
Anna Wasyl, Chief Financial Officer and Interim CEO of Tristel, commented: "We are delighted to deliver another year of significant growth with strong demand for our infection prevention products globally.
"We continue to meet our performance targets of delivering double-digit revenue growth each year, and maintaining adjusted EBITDA margins of at least 25%. We remain debt-free, cash-generative, and confident in our ability to continue to sustain this momentum in the years ahead.
"We are very excited to welcome our new CEO, Chris Lee, to the Company on 1 August, and we look forward to his contribution to the business as we drive further growth and overseas expansion in the new financial year."
For further information please contact:
|
Tristel plc |
Via Walbrook PR |
||
|
Anna Wasyl, Interim CEO |
|||
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or tristel@walbrookpr.com |
||
|
Paul McManus / Lianne Applegarth / Anna Dunphy |
Mob: 07980 541 893/ 07584 391 303/ 07876 741 001 |
||
|
Cavendish Capital Markets Ltd |
Tel: 020 7220 0500 |
||
|
Geoff Nash / Callum Davidson / Joe Smith (Corporate Finance) |
|||
|
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales) |
|||
About Tristel plc
Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals with products under the Tristel brand, which also encompasses its sporicidal surface disinfection range offered as a sustainable alternative to commonly used pre‑wetted plastic wipe.
Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries.
Performance targets
The Company targets delivering double-digit revenue growth annually, an adjusted EBITDA margin of at least 25% and a continuing progressive year-on-year growth in dividends, underpinned by robust cash generation.
The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).
For more information about Tristel's product range please visit: https://tristel.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.